Dynamic phenotypes of preclinical and clinical obesity in relation to new‐onset cancer risk: A longitudinal analysis from the UK biobank
Diabetes, Obesity and Metabolism · 2025-09 · 27 (9) · 5291-5301
DOI: 10.1111/dom.16582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 02.07.2025. Verfasst von Manrong Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai…. Hauptthemen laut MEDLINE: Neoplasms, Obesity. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lake Health & Louisiana State University, National Natural Science Foundation of China, NIGMS NIH HHS.
Abstract (Originalsprache)
Aim
The definition of clinical obesity was newly announced. Our study aims to investigate the relationship between different states of obesity and dysfunctions due to obesity with cancer incidence and mortality.
Methods
The prospective cohort study from the UK Biobank included 220 016 participants. Anthropometric parameters, in combination with obesity‐induced dysfunctions, were used to diagnose clinical obesity. Six clusters were categorized according to individual's baseline and follow‐up dysfunction status. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for cancer incidence risk were estimated using the landmark analysis.
Results
After a mean follow‐up period of 11.0 years, a total of 24 066 cancer incidence was observed. Using Cluster 1 (participants without obesity and dysfunction at baseline and during follow‐up) as the reference group, Cluster 5 (preclinical obesity with follow‐up dysfunctions; HR = 3.17, 95% CI: 3.05–3.29) exhibited the highest multivariable‐adjusted cancer incidence risk, while Cluster 4 (preclinical obesity without follow‐up dysfunctions; HR = 0.88, 95% CI: 0.85–0.92) showed the lowest. Additionally, the fully adjusted HRs for cancer mortality showed the highest in Cluster 6 (clinical obesity; HR = 1.82, 95% CI: 1.65–2.00), compared with Cluster 1. Site‐specific analyses showed consistently higher cancer risks in Cluster 5 and 6 across various types of cancer, notably the incidence of pancreatic cancer and the mortality of prostate or bladder cancer.
Conclusion
Obesity‐induced dysfunction was significantly associated with cancer risk. For future clinical practice, the early identification and intervention of clinical obesity and obesity‐induced dysfunctions are of critical importance for reducing cancer risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai K…
- Chronic Disease Epidemiology Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Förderung
- Lake Health & Louisiana State University
- National Natural Science Foundation of China
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Xu, M., Li, M., Zhang, Y., Li, L., Shen, Y., & Hu, G. (2025). Dynamic phenotypes of preclinical and clinical obesity in relation to new‐onset cancer risk: A longitudinal analysis from the UK biobank. Diabetes, Obesity and Metabolism, 27(9), 5291-5301. https://doi.org/10.1111/dom.16582
Vancouver
Xu M, Li M, Zhang Y, Li L, Shen Y, Hu G. Dynamic phenotypes of preclinical and clinical obesity in relation to new‐onset cancer risk: A longitudinal analysis from the UK biobank. Diabetes, Obesity and Metabolism. 2025;27(9):5291-5301. doi:10.1111/dom.16582
BibTeX
@article{Xu2025,
author = {Xu, Manrong and Li, Menghan and Zhang, Yawen and Li, Lianxi and Shen, Yun and Hu, Gang},
title = {Dynamic phenotypes of preclinical and clinical obesity in relation to new‐onset cancer risk: A longitudinal analysis from the UK biobank},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {9},
pages = {5291--5301},
doi = {10.1111/dom.16582}
}
EUVIMED